Decades after their discovery by bioprospectors, amphibian-derived analgesics continue to attract scientific attention.

If successful, the treatments could alleviate patients’ pain by reducing inflammation.

Compounds in the arachnids’ venom interact with ion channels to both cause and block pain.

In tiny doses, the pufferfish’s tetrodotoxin can be turned into a pain-relieving ion channel blocker.

Arachnids harbor a plentiful array of molecules that target mammalian pain receptors.

Venomous centipedes may harbor a clue to the creation of a successful pain-killing compound for humans.

Studying cone snail venom has yielded novel pain pathways, but the peptides that function as toxins are difficult to translate into drugs.

Painful snake bites may hold clues to developing analgesic drugs.

In a new and improved in vitro model of the blood-brain barrier, scientists allow a milieu of cells to grow together and form multicellular structures.

A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool?